Juan Rodriguez

Dr. Juan Rodriguez

orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2018 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
JRJuan Rodriguez
Juan Rodriguez
CGCarola Gallo‐Rodriguez
Carola Gallo‐Rodriguez

26 July 2002 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
EEEleonora Elhalem
Eleonora Elhalem
BBBrian N. Bailey
Brian N. Bailey
RDRoberto Docampo
Roberto Docampo
IUIstván Ujváry
István Ujváry
SSSergio Szajnman
Sergio Szajnman
JRJuan Rodriguez
Juan Rodriguez

10 August 2023 in Chemistry – A European Journal
Verified
Journal Article
Closed access
JSJuan M. Sonego
Juan M. Sonego
SDSheila I. de Diego
Sheila I. de Diego
SSSergio H. Szajnman
Sergio H. Szajnman
CGCarola Gallo‐Rodriguez
Carola Gallo‐Rodriguez
JRJuan Rodriguez
Juan Rodriguez

12 July 2024 in ChemMedChem
Verified
Journal Article
Closed access
CGCarola Gallo‐Rodriguez
Carola Gallo‐Rodriguez
JRJuan Rodriguez
Juan Rodriguez

1 February 2006 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
GLGuadalupe E. G. Linares
Guadalupe E. G. Linares
EREsteban L. Ravaschino
Esteban L. Ravaschino
JRJuan Rodriguez
Juan Rodriguez
The progresses made in the field of drug design to combat tropical protozoan parasitic diseases, such as Chagas disease, leishmaniasis, and sleeping sickness are discussed. This article is focused on different approaches based on unique aspects of parasites biochemistry and physiology, selecting the more promising molecular targets for drug design. In spite of the enormous amount of work on the above features, the chemotherapy for all of these diseases remains unsolved. It is based on old and fairly not specific drugs associated, in several cases, with long-term treatments and severe side effects. Drug resistance and different strains susceptibility are further drawbacks of the existing chemotherapy. In this review article, a thorough analysis of selected molecular targets, mainly those that are significantly different compared with the mammalian host or, even, are not present in mammals would be described in terms of their potencial usefulness for drug design. Therefore, this article covers rational approaches to the chemotherapeutic control of these parasitic infections, such as the progresses in the search for novel metabolic pathways in parasites that may be essential for parasites survival but with no counterpart in the host. Ergosterol biosynthesis is a very interesting example. There are many enzymes involved in this biosynthetic pathway such us squalene synthase, farnesylpyrophosphate synthase, and other enzymes that are able to deplete endogenous sterols will be treated in this article. The enzymes involved in trypanothione biosynthesis, glutathionyl spermidine synthetase and trypanothione synthetase do not have an equivalent in mammals, and therefore it can be predicted low toxicity for compounds that are able to produce highly selective inhibition. Trypanothione reductase (TR), glyceraldehyde-3-phosphate dehydrogenase, dihydrofolate reductase, prenyltransferases, ornithine decarboxylase, etc, will be thoroughly analyzed. The design of specific inhibitors of such metabolic activities as possible means of controlling the parasites without damaging the hosts will be presented. The recent advances in the biochemistry of pathogenic parasites including the discovery of novel organelles will be discussed.

1 September 1993 in Tetrahedron Letters
Verified
Journal Article
Closed access
JRJuan Rodriguez
Juan Rodriguez
VMVictor E. Marquez
Victor E. Marquez
MNMarc C. Nicklaus
Marc C. Nicklaus
JBJoseph Barchi
Joseph Barchi